MASS SPECTROMETRY REVIEWS, published by Wiley, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications across a multitude of scientific disciplines. With an ISSN of 0277-7037 and an E-ISSN of 1098-2787, the journal has established itself as a vital resource within the realms of Analytical Chemistry, Biochemistry, Genetics, Condensed Matter Physics, and Spectroscopy, achieving Q1 status across these categories in 2023. As a testament to its significant contribution to scholarly research, it boasts impressive Scopus rankings, including a rank of #2 out of 76 in Chemistry - Spectroscopy and #4 out of 156 in Chemistry - Analytical Chemistry, placing it in the 97th percentile and above. Emphasizing high-quality, peer-reviewed research, MASS SPECTROMETRY REVIEWS serves as an essential platform for researchers, professionals, and students aiming to stay abreast of cutting-edge developments and methodologies in mass spectrometry. The journal is committed to fostering a deeper understanding of mass spectrometric techniques while also contributing to interdisciplinary advancements, making it a valuable addition to any academic library. Authors seeking to disseminate their work in a journal with a strong reputation and impact in the scientific community will find MASS SPECTROMETRY REVIEWS an ideal venue.

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

Molecular Systems Biology, published by SpringerNature, is a premier open access journal that has been a cornerstone in advancing the fields of biological science since its inception in 2005. With its ISSN 1744-4292, this journal exemplifies high scholarly standards, boasting an impressive suite of impact factors, including Q1 rankings across various disciplines such as Agricultural and Biological Sciences, Biochemistry, Genetics and Molecular Biology, and more, highlighting its significant contribution to the scientific community. The journal offers robust access options to facilitate innovative research dissemination, reaching a global audience while maintaining a commitment to fostering collaboration and dialogue among researchers, professionals, and students. With a focus on integrating quantitative approaches to biological systems, Molecular Systems Biology plays a vital role in addressing complex biological questions, paving the way for groundbreaking discoveries and advancements in healthcare, environmental sustainability, and functional genomics.

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Welcome to Critical Reviews in Biochemistry and Molecular Biology, a premier academic journal published by Taylor & Francis Ltd, dedicated to advancing the fields of biochemistry and molecular biology. With an impressive impact factor and a Q1 ranking in both Biochemistry and Molecular Biology for 2023, this journal serves as a vital resource for researchers, professionals, and students eager to engage with cutting-edge reviews and analyses that synthesize the latest developments in these dynamic areas of study. Since its inception in 1972, the journal has maintained a commitment to high-quality scholarship, providing a platform for critical discussions that accelerate the discovery and understanding of biochemical processes and molecular interactions. Although not open access, its robust editorial peer-review process ensures that published articles meet the highest standards of scientific rigor, making it a trusted source for the scientific community. As we continue to converge toward 2024, we invite you to explore the extensive array of topics and findings that have shaped contemporary biochemistry and molecular biology.

MOLECULAR CANCER RESEARCH, published by the American Association for Cancer Research, stands as a pivotal journal in the fields of cancer research, molecular biology, and oncology. With an impressive impact factor and recognized as a Q1 journal in its respective categories for 2023, it serves as an essential resource for researchers, professionals, and students aimed at advancing our understanding of cancer mechanisms and therapies. The journal, identified by the ISSN 1541-7786 and E-ISSN 1557-3125, provides a platform for cutting-edge research and clinical applications, emphasizing innovation and collaboration within the scientific community. With its focus on high-quality, peer-reviewed articles, MOLECULAR CANCER RESEARCH is vital for anyone looking to stay abreast of significant advancements in cancer biology and treatment strategies. For more details and to access the journal's content, please visit the publisher's link.

GROWTH FACTORS, published by Taylor & Francis Ltd, is a prestigious journal dedicated to advancing the field of cell biology, clinical biochemistry, and endocrinology. With an ISSN of 0897-7194 and an E-ISSN of 1029-2292, this journal has served as a vital platform for the dissemination of groundbreaking research since its inception in 1988. Although it operates without an Open Access model, GROWTH FACTORS focuses on providing high-quality, peer-reviewed articles that explore the intricate roles of growth factors in biological processes and their implications in health and disease. Holding a Q4 ranking in Cell Biology and Q3 rankings in Clinical Biochemistry and Endocrinology according to the 2023 category quartiles, the journal is well-regarded in its field and plays a crucial role in informing researchers, professionals, and students alike about the latest findings and innovations in these areas. The journal's commitment to fostering scientific dialogue ensures that it remains a key resource for those looking to enhance their understanding of growth factors and their applications in clinical settings.

Proteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.